$Mobile-health Network Solutions(MNDR)$ So what is the issue here.  

1) product has toxicity issues,

2) results are misleading,

3) limited market for their drug,

4) problems raising money? Etc.

Preclinical results worth nothing under this market conditions. Wait for phase 1 data release[LOL][LOL][LOL]

# US Stocks Opportunities

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet